NCI-H2452Homo sapiens (Human)Cancer cell line
Also known as: NCIH2452, H-2452, H2452
Quick Overview
Malignant mesothelioma cell line with BAP1 mutations and Hippo pathway alterations.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1553 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Lung, pleura[UBERON:UBERON_0000977] |
Donor Information
| Age Category | Adult |
|---|---|
| Sex | Male |
Disease Information
| Disease | Pleural mesothelioma |
|---|---|
| Lineage | Pleura |
| Subtype | Pleural Mesothelioma, Biphasic Type |
| OncoTree Code | PLBMESO |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000092_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | BAP1 | p.Ala95Asp (c.284C>A) | Heterozygous | - | PubMed=26011428, PubMed=21642991 |
| Gene deletion | CDKN2A | - | Homozygous | Possible | PubMed=26870271 |
| Gene deletion | BAP1 | - | Heterozygous | - | PubMed=21642991 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
Aldige C.R., Wistuba I.I., Minna J.D.
J. Cell. Biochem. 121:3986-3999(2020).
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Nat. Commun. 10:3574.1-3574.11(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Posner B.A., Minna J.D., Kim H.S., White M.A.
Cell 173:864-878.e29(2018).
E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in merlin-negative malignant mesothelioma cells.
Kato T., Sato T., Yokoi K., Sekido Y.
Oncogene 36:5522-5531(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells.
Yokoi K., Sekido Y.
Cancer Sci. 106:990-999(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
Asamura H., Gemma A., Yamada T.
J. Thorac. Oncol. 10:844-851(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.
Rice D.C., Tsao A., Wistuba I.I.
J. Thorac. Oncol. 9:998-1007(2014).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
Powell S.N., Zhou Q., Shen R.-L., Olshen A.B., Rusch V.W., Ladanyi M.
Nat. Genet. 43:668-672(2011).
LATS2 is a tumor suppressor gene of malignant mesothelioma.";
Sekido Y.
Cancer Res. 71:873-883(2011).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Oncogene 19:4632-4639(2000).
NCI-Navy Medical Oncology Branch cell line data base.";
Carney D.N., Minna J.D., Mulshine J.L.
J. Cell. Biochem. Suppl. 24:32-91(1996).